Value of mucosal assessment and biomarkers in inflammatory bowel disease

Expert Review of Gastroenterology and Hepatology

Volumn 4, Issue 3, 2010, Pages 285-291

  Stidham, Ryan W ^a   Higgins, Peter D R ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Biomarker; C reactive protein; Crohns disease; Fecal calprotectin; Fecal lactoferrin; Inflammatory bowel disease; Mucosal healing; Outcome; Ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; INFLIXIMAB; INTERLEUKIN 6; LACTOFERRIN; PROTEIN S 100; PROTEIN S100A12; TUMOR NECROSIS FACTOR ALPHA; UBE4A PROTEIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

BLOOD ANALYSIS; COLON RESECTION; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE EXACERBATION; ENTERITIS; FALSE POSITIVE RESULT; FECES ANALYSIS; GASTROINTESTINAL ENDOSCOPY; HEALING; HUMAN; INTESTINE MUCOSA; INTESTINE MUCOSA HEALING; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PROGNOSIS; RELAPSE; REMISSION; REVIEW; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS; BLOOD; INFLAMMATORY BOWEL DISEASES; PATHOLOGY;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; PROGNOSIS;

EID: 77953278068     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.10.22     Document Type: Review

References (55)

1. Caprilli R, Gassull MA, Escher JC et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 55(Suppl. 1), i36-i58 (2006).
2. Wexner SD, Rosen L, Lowry A et al. Practice parameters for the treatment of mucosal ulcerative colitis - supporting documentation. The Standards Practice Task Force. The American Society of Colon and Rectal Surgeons. Dis. Colon Rectum 40(11), 1277-1285 (1997).
3. Ananthakrishnan AN, Weber LR, Knox JF et al. Permanent work disability in Crohn's disease. Am. J. Gastroenterol. 103(1), 154-161 (2008).
4. Kappelman MD, Rifas-Shiman SL, Porter CQ et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 135(6), 1907-1913 (2008).
5. Casellas F, Rodrigo L, Nino P, Pantiga C, Riestra S, Malagelada JR. Sustained improvement of health-related quality of life in Crohn's disease patients treated with infliximab and azathioprine for 4 years. Inflamm. Bowel Dis. 13(11), 1395-1400 (2007).
6. Bouhnik Y, Lemann M, Mary JY et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 347(8996), 215-219 (1996).
7. Solberg IC, Vatn MH, Hoie O et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin. Gastroenterol. Hepatol. 5(12), 1430-1438 (2007).
8. Cosnes J, Cattan S, Blain A et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm. Bowel Dis. 8(4), 244-250 (2002).
9. Caspersen S, Elkjaer M, Riis L et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin. Gastroenterol. Hepatol. 6(11), 1212-1217; quiz 1176 (2008).
10. Lees CW, Ali AI, Thompson AI et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment. Pharmacol. Ther. 29(3), 286-297 (2009).
11. Seiderer J, Zech CJ, Diebold J et al. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. Eur. J. Gastroenterol. Hepatol. 18(5), 553-555 (2006).
12. Toruner M, Loftus EV Jr, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134(4), 929-936 (2008).
13. Allez M, Lemann M, Bonnet J, Cattan P, Jian R, Modigliani R. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am. J. Gastroenterol. 97(4), 947-953 (2002).
14. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 99(4), 956-963 (1990).
15. Reinisch W, Rutgeerts PJ, Panaccione R et al. Prediction of long-term clinical remission for adalimumab-treated patients with Crohn's disease by identification of approriate dichotomizing points for SES-CD. Presented at: Digestive Disease Week 2010, American Gastroenterological Association. New Orleans, LA, USA, 1-5 May, 2010 (Abstract 41a).
16. Froslie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133(2), 412-422 (2007).
17. Baert F, Moortgat L, Van Assche G et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 138(2), 463-468 (2010).
18. Schnitzler F, Fidder H, Ferrante M et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm. Bowel Dis. 15(9), 1295-1301 (2009).
19. Andersen K, Vogt C, Blondin D et al. Multi-detector CT-colonography in inflammatory bowel disease: prospective analysis of CT-findings to high-resolution video colonoscopy. Eur. J. Radiol. 58(1), 140-146 (2006).
20. Ergen FB, Akata D, Hayran M et al. Magnetic resonance colonography for the evaluation of colonic inflammatory bowel disease: correlation with conventional colonoscopy. J. Comput. Assist. Tomogr. 32(6), 848-854 (2008).
21. Koilakou S, Sailer J, Peloschek P et al. Endoscopy and MR enteroclysis: Equivalent tools in predicting clinical recurrence in patients with Crohn's disease after ileocolic resection. Inflamm. Bowel Dis. 16(2), 198-203 (2009).
22. Bozkurt T, Richter F, Lux G. Ultrasonography as a primary diagnostic tool in patients with inflammatory disease and tumors of the small intestine and large bowel. J. Clin. Ultrasound 22(2), 85-91 (1994).
23. Fraquelli M, Colli A, Casazza G et al. Role of US in detection of Crohn disease: meta-analysis. Radiology 236(1), 95-101 (2005).
24. Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut 58(6), 859-868 (2009).
25. Sugi K, Saitoh O, Hirata I, Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am. J. Gastroenterol. 91(5), 927-934 (1996).
26. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 34(1), 50-54 (1999).
27. Costa F, Mumolo MG, Bellini M et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig. Liver Dis. 35(9), 642-647 (2003).
28. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig. Liver Dis. 41(1), 56-66 (2009).
29. Hanai H, Takeuchi K, Iida T et al. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig. Dis. Sci. 49(9), 1438-1443 (2004).
30. Jones J, Loftus EV Jr, Panaccione R et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin. Gastroenterol. Hepatol. 6(11), 1218-1224 (2008).
31. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 39(10), 1017-1020 (2004).
32. Sipponen T, Savilahti E, Karkkainen P et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-a therapy for Crohn's disease. Inflamm. Bowel Dis. 14(10), 1392-1398 (2008).
33. Ho GT, Lee HM, Brydon G et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am. J. Gastroenterol. 104(3), 673-678 (2009).
34. Gisbert JP, Bermejo F, Perez-Calle JL et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm. Bowel Dis. 15(8), 1190-1198 (2009).
35. Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm. Bowel Dis. 15(11), 1746-1754 (2009).
36. D'Inca R, Dal Pont E, Di Leo V et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am. J. Gastroenterol. 103(8), 2007-2014 (2008).
37. Sorrentino D, Paviotti A, Terrosu G, Avellini C, Geraci M, Zarifi D. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin. Gastroenterol. Hepatol. DOI: 10.1016/j.cgh.2010.01.016 (2010) (Epub ahead of print).
38. Kolho KL, Raivio T, Lindahl H, Savilahti E. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand. J. Gastroenterol. 41(6), 720-725 (2006).
39. Darlington GJ, Wilson DR, Lachman LB. Monocyte-conditioned medium, interleukin-1, and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro. J. Cell Biol. 103(3), 787-793 (1986).
40. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am. J. Gastroenterol. 103(1), 162-169 (2008).
41. Rodgers AD, Cummins AG. CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease. Dig. Dis. Sci. 52(9), 2063-2068 (2007).
42. Brull DJ, Serrano N, Zito F et al. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 23(11), 2063-2069 (2003).
43. Haukim N, Bidwell JL, Smith AJ et al. Cytokine gene polymorphism in human disease: on-line databases, supplement 2. Genes Immun. 3(6), 313-330 (2002).
44. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm. Bowel Dis. 11(8), 707-712 (2005).
45. Denis MA, Reenaers C, Fontaine F, Belaiche J, Louis E. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. Inflamm. Bowel Dis. 13(9), 1100-1105 (2007).
46. Boirivant M, Leoni M, Tariciotti D, Fais S, Squarcia O, Pallone F. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J. Clin. Gastroenterol. 10(4), 401-405 (1988).
47. Consigny Y, Modigliani R, Colombel JF, Dupas JL, Lemann M, Mary JY. A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm. Bowel Dis. 12(7), 551-557 (2006).
48. Schnitzler F, Fidder H, Ferrante M et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 58(4), 492-500 (2009).
49. Papadakis KA, Yang H, Ippoliti A et al. Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm. Bowel Dis. 13(5), 524-530 (2007).
50. Papp M, Altorjay I, Norman GL et al. Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. Inflamm. Bowel Dis. 13(8), 984-992 (2007).
51. Spivak J, Landers CJ, Vasiliauskas EA et al. Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease. Inflamm. Bowel Dis. 12(12), 1122-1130 (2006).
52. Sakiyama T, Fujita H, Tsubouchi H. Autoantibodies against ubiquitination factor E4A (UBE4A) are associated with severity of Crohn's disease. Inflamm. Bowel Dis. 14(3), 310-317 (2008).
53. Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am. J. Gastroenterol. 102(9), 2058-2069 (2007).
54. Kaser A, Tilg H. Novel therapeutic targets in the treatment of IBD. Expert Opin. Ther. Targets 12(5), 553-563 (2008).
55. Kmiec Z. Cytokines in inflammatory bowel disease. Arch. Immunol. Ther. Exp. (Warsz.) 46(3), 143-155 (1998).